Weiting Kang

8PUBLICATIONS
16CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersMolecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 08, 2026
YTHDF2 drives malignant progression in cutaneous melanoma through m⁶A-dependent HMOX1-mediated ferroptosis.

|Dec 18, 2025
Targeting the SMAD3/CISD2 axis suppresses bladder cancer progression by promoting ferroptosis in mesenchymal-like bladder cancer cells.

Yulin Sun, Jianghui Wang, Da Gu

|Dec 24, 2021
Erratum to "Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis".

Chenglin Han, Zilong Wang, Shuxiao Chen

|Aug 06, 2021
Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer.

Hui Xiong, Hui Gao, Jinding Hu

|Mar 17, 2021
Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.

Qiang Wang, Jinding Hu, Weiting Kang

|Feb 01, 2021
Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis.

Chenglin Han, Zilong Wang, Shuxiao Chen

Pageof 2

Frequent Collaborators

4 joint publications

Zilian Cui

3 joint publications

Da Gu

3 joint publications

Hanbo Wang

3 joint publications

Qinghua Xia